文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌SBRT五次日照射36.25 Gy与40 Gy的倾向评分匹配分析

36.25 Gy versus 40 Gy in five fractions of curative stereotactic body radiotherapy for prostate cancer: a propensity score-matched analysis.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-09-19

本研究回顾性分析863例前列腺癌患者,经倾向评分匹配后530例接受五次日间照射SBRT,比较36.25 Gy与40 Gy的PSA复发及毒性。5年无事件生存率分别为90%和88%(p=0.37),PSA无复发生存率95%和93%(p=0.76),36.25 Gy组3级胃肠道和泌尿生殖毒性分别为2.3%和1.3%。

要点

  • 36.25 Gy与40 Gy组5年无事件生存率分别为90%和88%,差异无统计学意义。
  • 36.25 Gy组3级胃肠道和泌尿生殖毒性分别为2.3%和1.3%,无5级毒性。
  • 研究为回顾性设计,结果应视为假设生成性。

核心结论

  • 36.25 Gy方案在无事件生存方面可能不劣于40 Gy,且可能与更少的4级毒性和更好的泌尿生活质量相关。

研究设计与样本

  • 单中心回顾性研究,2016至2025年连续863例前列腺癌患者,经倾向评分匹配后530例纳入分析。
  • 匹配因素包括年龄、治疗前PSA水平、活检Gleason评分、临床T分期、NCCN风险分类和同期雄激素剥夺治疗。
  • 患者接受总剂量36.25 Gy或40 Gy的五次SBRT,隔日照射。
  • 预设非劣效界值为风险比1.40。

主要发现

  • 36.25 Gy组和40 Gy组分别发生16例和10例PSA复发,18例和10例死亡。
  • 5年无事件生存率分别为90%和88%(p=0.37),风险比为0.76(95%CI 0.42-1.39;p=0.37)。
  • 5年PSA无复发生存率分别为95%和93%(p=0.76)。
  • 36.25 Gy组298例中3级胃肠道和泌尿生殖毒性发生率分别为2.3%和1.3%。
  • 40 Gy组565例中3级胃肠道毒性发生率为1.9%,≥3级泌尿生殖毒性发生率为0.8%,无5级毒性。

关键数值与推荐

  • 预设非劣效界值为风险比1.40。
  • 5年无事件生存率36.25 Gy组90% vs 40 Gy组88%(p=0.37)。
  • 5年PSA无复发生存率36.25 Gy组95% vs 40 Gy组93%(p=0.76)。

临床怎么用

  • 对于前列腺癌SBRT,36.25 Gy五次方案可作为与40 Gy五次方案比较的候选方案,但需考虑回顾性研究的局限性。

局限性

  • 回顾性设计,结果应视为假设生成性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to determine whether 36.25 Gy was inferior to 40 Gy in terms of prostate-specific antigen (PSA) recurrence following stereotactic body radiation therapy (SBRT) for prostate cancer. METHODS: We retrospectively reviewed the medical records of 863 consecutive patients with prostate cancer treated at a single institution between 2016 and 2025. Propensity score (PS) matching based on age, pre-treatment PSA level, biopsy Gleason score, clinical T-stage, National Comprehensive Cancer Network (NCCN) risk classification, and concomitant androgen-deprivation therapy (ADT) yielded 530 patients for analysis. Patients received SBRT at a total dose of 36.25 or 40 Gy in five fractions administered every other day. The prespecified non-inferiority margin was a hazard ratio of 1.40. RESULTS: After PS matching, no significant differences remained in baseline characteristics that had differed significantly between the two groups before matching. In the 36.25-Gy and 40-Gy groups, respectively, 16 and 10 PSA recurrences and 18 and 10 deaths occurred. Four PSA recurrences (15%) occurred over 5 years. The 5-year event-free survival (EFS) rates were 90% with 36.25 Gy and 88% with 40 Gy (p = 0.37). The hazard ratio for EFS with 36.25 Gy versus 40 Gy was 0.76 (95% confidence interval [CI], 0.42-1.39; p = 0.37). The 5-year PSA recurrence-free rates were 95% and 93%, respectively (p = 0.76). Among the 298 patients receiving 36.25 Gy, grade 3 gastrointestinal (GI) and genitourinary (GU) toxicities occurred in 2.3% and 1.3%, respectively. Among the 565 patients receiving 40 Gy, grade 3 or GI toxicity occurred in 1.9%, and grade ≥ 3 GU toxicity occurred in 0.8%. No grade 5 toxicity occurred. Urinary and bowel quality of life (QOL) scores decreased at 1 month and returned to near-baseline levels by 3 months. CONCLUSIONS: In this retrospective study, the findings suggest that the 36.25-Gy regimen may be non-inferior to 40 Gy for EFS and may be associated with fewer grade 4 toxicities and better urinary QOL. Given the retrospective design, these findings should be considered hypothesis-generating.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yamashita H, Sugahara D, Sawayanagi S, et al. 36.25 Gy versus 40 Gy in five fractions of curative stereotactic body radiotherapy for prostate cancer: a propensity score-matched analysis. Clin Transl Radiat Oncol. 2026. PMID: 42830848. doi:10.1016/j.ctro.2026.101281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。